Acute coronary syndromes and diabetes mellitus a winning ticket for prasugrel

Circulation

Volumn 118, Issue 16, 2008, Pages 1607-1608

  Fuster, Valentin ^a   Farkouh, Michael E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary disease; Diabetes mellitus; Editorials; Myocardial infarction; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR; INSULIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG METABOLISM; EDITORIAL; ENDOTHELIAL DYSFUNCTION; GLYCOSYLATION; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HYPERTENSION; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY FAILURE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; CORONARY ARTERY THROMBOSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE;

ACUTE CORONARY SYNDROME; CORONARY THROMBOSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES;

EID: 55949100439     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.813501     Document Type: Editorial

References (14)

1. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765-775.
2. Farkouh ME, Rayfield E, Fuster V. Diabetes and cardiovascular disease. In: Fuster V, O'Rourke RA, Walsh RA, Poole-Wilson P, eds. Hurst's The Heart. 12th ed. New York, NY. McGraw-Hill; 2001:2073-2102.
3. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004;44:2293-2300.
4. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med. 1975;82:733-738.
5. Ferreira IA, Mocking AI, Feijge MA, Gorter G, Van Haeften TW, Heemskerk JW, Akkerman JW. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26:417-422.
6. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
7. Angiolillo DJ, Showmaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation. 2007;115:1-9.
8. Savi P, Herbert JM. Clopidogrel and toclopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005;31:174-183.
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C. Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-1516.
10. Jakubowski JA, Winters KJ, Naganuma H. Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent: a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25:357-374.
11. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann F-J, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932.
12. Sabatine MS, Braunwald E. Will diabetes save the platelet blockers? Circulation. 2001;104:2759-2761.
13. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767-2771.
14. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FWA, Goodman SG, Corbalan R, Purdy DA, Murphy S, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in TRITON - TIMI 38. Circulation. 2008;118:1626-1636.